Why You Should Not Use Ivermectin to Treat or Prevent COVID-19
Using the Drug ivermectin to treat COVID-19 can be dangerous and even lethal. The FDA has not approved the drug for that purpose.
More from U.S. FDA
FDA Approves First COVID-19 Vaccine
FDA approved the first COVID-19 vaccine, now marketed as Comirnaty, for the prevention of COVID-19 disease in individuals 16 years of age and older.
FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine
Today, the FDA issued the first EUA for a vaccine for the prevention of COVID-19 caused by SARS-CoV-2 in individuals 16 years of age and older.
Pre-Market Consultation for Human Food Made Using Animal Cell Culture
Before Entering the U.S. Market, the Food Must Meet Other Federal Requirements
FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Children 5 through 11 Years of Age
FDA authorized the emergency use of the Pfizer-BioNTech COVID-19 Vaccine for the prevention of COVID-19 to include children 5 through 11 years of age.
What is Refind?
Every day Refind picks the most relevant links from around the web for you. Picking only a handful of links means focusing on what’s relevant and useful. We favor timeless pieces—links with long shelf-lives, articles that are still relevant one month, one year, or even ten years from now. These lists of the best resources on any topic are the result of years of careful curation.
How does Refind curate?
It’s a mix of human and algorithmic curation, following a number of steps:
- We monitor 10k+ sources and 1k+ thought leaders on hundreds of topics—publications, blogs, news sites, newsletters, Substack, Medium, Twitter, etc.
- In addition, our users save links from around the web using our Save buttons and our extensions.
- Our algorithm processes 100k+ new links every day and uses external signals to find the most relevant ones, focusing on timeless pieces.
- Our community of active users gets the most relevant links every day, tailored to their interests. They provide feedback via implicit and explicit signals: open, read, listen, share, mark as read, read later, «More/less like this», etc.
- Our algorithm uses these internal signals to refine the selection.
- In addition, we have expert curators who manually curate niche topics.
The result: lists of the best and most useful articles on hundreds of topics.
How does Refind detect «timeless» pieces?
We focus on pieces with long shelf-lives—not news. We determine «timelessness» via a number of metrics, for example, the consumption pattern of links over time.
How many sources does Refind monitor?
We monitor 10k+ content sources on hundreds of topics—publications, blogs, news sites, newsletters, Substack, Medium, Twitter, etc.
Can I submit a link?
Indirectly, by using Refind and saving links from outside (e.g., via our extensions).
How can I report a problem?
When you’re logged-in, you can flag any link via the «More» (...) menu. You can also report problems via email to hello@refind.com
Who uses Refind?
450k+ smart people start their day with Refind. To learn something new. To get inspired. To move forward. Our apps have a 4.9/5 rating.
Is Refind free?
Yes, it’s free!
How can I sign up?
Head over to our homepage and sign up by email or with your Twitter or Google account.